Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EWTX
- Price
- 11.42
- Stock movement down
- -0.15 (-1.30%)
- Company name
- Edgewise Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.08B
- Ent value
- 1.06B
- Price/Sales
- 480.17
- Price/Book
- 2.21
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -28.31%
- 3 year return
- 6.18%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
EWTX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 480.17 |
| Price to Book | 2.21 |
| EV to Sales | 470.22 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 94.69M |
| EPS (TTM) | -1.32 |
| FCF per share (TTM) | -1.17 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.25M |
| Gross profit (TTM) | 660.00K |
| Operating income (TTM) | -147.15M |
| Net income (TTM) | -124.29M |
| EPS (TTM) | -1.32 |
| EPS (1y forward) | -1.85 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 29.31% |
| Operating margin (TTM) | -6534.37% |
| Profit margin (TTM) | -5519.27% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 44.81M |
| Net receivables | 0.00 |
| Total current assets | 499.44M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 511.28M |
| Accounts payable | 5.65M |
| Short/Current long term debt | 4.44M |
| Total current liabilities | 18.96M |
| Total liabilities | 22.41M |
| Shareholder's equity | 488.88M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -108.90M |
| Capital expenditures (TTM) | 1.20M |
| Free cash flow (TTM) | -110.10M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -25.42% |
| Return on Assets | -24.31% |
| Return on Invested Capital | -25.37% |
| Cash Return on Invested Capital | -22.48% |
Edgewise Therapeutics' stock soars on positive Becker Muscular Dystrophy trial results. Learn why EWTX is a promising buy with derisked programs.
March 10, 2025
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 11.48 |
| Daily high | 11.85 |
| Daily low | 11.28 |
| Daily Volume | 1.28M |
| All-time high | 36.62 |
| 1y analyst estimate | 45.86 |
| Beta | 0.15 |
| EPS (TTM) | -1.32 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| EWTX | S&P500 | |
| Current price drop from All-time high | -68.81% | -12.89% |
| Highest price drop | -84.69% | -56.47% |
| Date of highest drop | 10 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -57.27% | -11.07% |
| Avg time to new high | 509 days | 12 days |
| Max time to new high | 909 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.08B
Marketcap category
Small-cap
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Employees
108
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page